Robinhood Asset Management LLC Makes New Investment in Neurocrine Biosciences, Inc. $NBIX

Robinhood Asset Management LLC bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 40,296 shares of the company’s stock, valued at approximately $5,715,000.

Several other institutional investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its position in Neurocrine Biosciences by 83.7% in the third quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock valued at $388,435,000 after buying an additional 1,263,633 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Neurocrine Biosciences by 11.0% during the third quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company’s stock worth $664,019,000 after buying an additional 468,405 shares in the last quarter. Two Sigma Investments LP bought a new position in shares of Neurocrine Biosciences in the third quarter valued at approximately $48,791,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Neurocrine Biosciences in the 2nd quarter worth approximately $42,933,000. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in shares of Neurocrine Biosciences by 228.9% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 411,660 shares of the company’s stock worth $57,789,000 after acquiring an additional 286,498 shares in the last quarter. 92.59% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Neurocrine Biosciences news, CEO Kyle Gano sold 36,400 shares of the company’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the completion of the sale, the chief executive officer owned 140,407 shares in the company, valued at approximately $18,632,008.90. The trade was a 20.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.80% of the company’s stock.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Acquisition expands Neurocrine’s commercial footprint by adding VYKAT XR (first/only FDA treatment for hyperphagia in Prader‑Willi Syndrome) and creates a three‑product commercial portfolio alongside INGREZZA® and CRENESSITY®. This supports long‑term revenue diversification. Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
• Positive Sentiment: Bank of America reiterated a Buy and raised its price target to $199, signaling bullish analyst conviction that the deal meaningfully increases upside despite a near‑term pipeline lull. Neurocrine Biosciences: Vykat XR Acquisition Unlocks Diversified Growth and Upside Potential Despite Near-Term Pipeline Lull
• Positive Sentiment: Needham reaffirmed a Buy with a $185 target, reinforcing that some buy‑side analysts view the acquisition as value‑creating. Needham & Company Reaffirms Buy on Neurocrine
• Neutral Sentiment: Deal mechanics: Neurocrine will pay $53.00 per Soleno share in an all‑cash transaction valued at about $2.9 billion; a conference call was held to discuss terms. These are execution/funding facts investors will monitor. Neurocrine to buy Soleno Therapeutics for $2.9 billion
• Neutral Sentiment: Market validation for the premium: Soleno shares jumped strongly on the deal, highlighting investor appetite for Soleno’s assets and the strategic rationale for Neurocrine. Soleno Therapeutics (SLNO) Soars 32% on $2.9-Billion Merger
• Negative Sentiment: Some analysts remain cautious: BMO kept a Hold and a $140 target, flagging long‑term execution risks for Ingrezza and orphan market rollouts that could offset acquisition benefits. Balanced View on Neurocrine Biosciences: Favorable Soleno Acquisition Prospects Offset by Long-Term Ingrezza and Orphan Market Execution Risks
• Negative Sentiment: Short‑term headwinds: Neurocrine’s stock initially dropped on the announcement (acquirer sell‑off is common after M&A news) as investors digest the $2.9B cash outlay, integration risk and near‑term pipeline cadence. This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal.
• Negative Sentiment: M&A call/transcript and analyst commentary highlight execution and integration questions investors should track (commercial roll‑out for VYKAT XR, orphan market uptake, and funding). Neurocrine Biosciences, Inc. (NBIX) M&A Call Transcript

Neurocrine Biosciences Trading Up 0.7%

Neurocrine Biosciences stock opened at $132.48 on Tuesday. The company has a market cap of $13.30 billion, a PE ratio of 28.43, a PEG ratio of 0.69 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $160.18. The company’s 50-day moving average is $131.52 and its two-hundred day moving average is $139.01.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 EPS for the quarter, missing the consensus estimate of $2.36 by ($0.48). The business had revenue of $805.50 million for the quarter, compared to analyst estimates of $804.21 million. Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The firm’s quarterly revenue was up 28.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.69 EPS. Research analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently commented on the company. Wedbush increased their target price on Neurocrine Biosciences from $149.00 to $151.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. BMO Capital Markets reduced their target price on shares of Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating on the stock in a research report on Thursday, February 12th. Needham & Company LLC reissued a “buy” rating and set a $185.00 price target on shares of Neurocrine Biosciences in a research note on Monday. Morgan Stanley restated an “equal weight” rating and issued a $175.00 price objective (up from $173.00) on shares of Neurocrine Biosciences in a research report on Thursday, January 8th. Finally, Wolfe Research started coverage on Neurocrine Biosciences in a report on Tuesday, February 24th. They set an “outperform” rating and a $160.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $175.10.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.